iRhythm Technologies (IRTC) to Raise $76 Million in IPO
In the last twelve months, iRhythm Technologies generated $48.8 million in revenue and had a net loss of $24 million. The company has a market-cap of $282.5 million.
J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.
iRhythm Technologies provided the following description of their company for its IPO: “We are a commercial-stage digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine-learning capabilities. Our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ECG, monitoring for patients at risk for arrhythmias. We have created a unique platform, called the ZIO Service, which combines an easy-to-wear and unobtrusive biosensor that can be worn for up to 14 days, called the ZIO Patch, with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. “.
iRhythm Technologies was founded in 2014 and has 356 employees. The company is located at 650 Townsend Street, Suite 500, San Francisco, CA 94103, US and can be reached via phone at (415) 632-5700 or on the web at https://www.iRhythmTech.com.
Receive News & Stock Ratings for iRhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRhythm Technologies and related stocks with our FREE daily email newsletter.